Provided is a pharmaceutical composition which is used in the treatment or prevention of early-stage osteoarthritis. Also provided is a method for producing same. The pharmaceutical composition and method of production therefor are based on the knowledge that it is possible to use IgM anti-Fas antibodies to alleviate the symptoms of osteoarthritis. Specifically, the pharmaceutical composition and method of production therefor are based the pharmaceutical composition is based on the knowledge that it is possible to use IgM anti-Fas antibodies to suppress the production of enzymes that breakdown the cartilage matrix. The pharmaceutical composition and method of production therefor are based on the knowledge that it possible to use IgM anti-Fas antibodies to improve cartilage matrix production.
